Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer
- 1 April 2003
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 10 (3), 234-241
- https://doi.org/10.1245/aso.2003.05.010
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancerCancer Gene Therapy, 1999
- The Epidermal Growth Factor Receptor and Its Inhibition in Cancer TherapyPharmacology & Therapeutics, 1999
- The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactionsFEBS Letters, 1997
- ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingThe EMBO Journal, 1997
- Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.Journal of Clinical Oncology, 1996
- Epidermal growth factor-related peptides and their relevance to gastrointestinal pathophysiologyGastroenterology, 1995
- Regulation of signal transduction and signal diversity by receptor oligomerizationTrends in Biochemical Sciences, 1994
- Activation of telomerase in a human tumor.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Signal transduction by receptors with tyrosine kinase activityCell, 1990
- Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodiesCell, 1985